Oncoc4, Inc.
Clinical trials sponsored by Oncoc4, Inc., explained in plain language.
-
New Dual-Action antibody takes on advanced cancers
Disease control Recruiting nowThis study tests a new drug called AI-081 in people with advanced solid tumors that have spread or cannot be removed by surgery. The drug is a bispecific antibody that targets two proteins (PD-1 and VEGF) involved in cancer growth and immune evasion. The trial has two phases: fir…
Phase: PHASE1, PHASE2 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Jun 16, 2026 12:54 UTC
-
New hope for lung cancer patients: experimental drug aims to extend life after other treatments fail
Disease control Recruiting nowThis study tests a new drug called gotistobart (ONC-392) against standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that worsened after prior immunotherapy. About 630 adults will receive either the new drug or chemotherapy every 3 weeks for up to…
Phase: PHASE3 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Jun 09, 2026 12:07 UTC
-
New hope for advanced cancers: experimental drug ONC-841 enters human trials
Disease control Recruiting nowThis study tests a new drug called ONC-841 in people with advanced solid tumors that have spread. The goal is to find a safe dose and see if it helps control the cancer. About 72 participants will receive the drug through an IV, either alone or with standard treatments.
Phase: PHASE1 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Jun 01, 2026 18:07 UTC